Cart
sales@molnova.com
GSK2795039
CAS No. 1415925-18-6
GSK2795039( —— )
Catalog No. M22686 CAS No. 1415925-18-6
GSK2795039 inhibits reactive oxygen species (ROS) production and NADPH consumption. GSK2795039 decreases apoptosis. GSK2795039 is an inhibitor of NADPH oxidase 2 (NOX2) (pIC50: 6 in different cell-free assays). GSK2795039 (25 μM; 24 hours) decreases the combinatory effect of FeSO4 and LPS-increased levels of apoptosis.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 2MG | 88 | In Stock |
|
| 5MG | 147 | In Stock |
|
| 10MG | 230 | In Stock |
|
| 25MG | 407 | In Stock |
|
| 50MG | 591 | In Stock |
|
| 100MG | 842 | In Stock |
|
| 200MG | Get Quote | In Stock |
|
| 500MG | Get Quote | In Stock |
|
| 1G | Get Quote | In Stock |
|
Biological Information
-
Product NameGSK2795039
-
NoteResearch use only, not for human use.
-
Brief DescriptionGSK2795039 inhibits reactive oxygen species (ROS) production and NADPH consumption. GSK2795039 decreases apoptosis. GSK2795039 is an inhibitor of NADPH oxidase 2 (NOX2) (pIC50: 6 in different cell-free assays). GSK2795039 (25 μM; 24 hours) decreases the combinatory effect of FeSO4 and LPS-increased levels of apoptosis.
-
DescriptionGSK2795039 inhibits reactive oxygen species (ROS) production and NADPH consumption. GSK2795039 decreases apoptosis. GSK2795039 is an inhibitor of NADPH oxidase 2 (NOX2) (pIC50: 6 in different cell-free assays). GSK2795039 (25 μM; 24 hours) decreases the combinatory effect of FeSO4 and LPS-increased levels of apoptosis. It also reduced the presence of caspase-3-positive PC12 cells.GSK2795039 (i.p.; 100 mg/kg; 1 hour before) reduces activity in a murine model of acute pancreatitis. It also decreases the levels of serum amylase triggered by systemic injection of cerulein.
-
In VitroGSK2795039 (25 μM; 24 hours) reduces the combinatory effect of FeSO4 and LPS-increased levels of apoptosis and reduced the presence of caspase-3-positive PC12 cells. Apoptosis Analysis Cell Line:PC12 cells Concentration:25 μM Incubation Time:24 hours Result:Reduced apoptosis among PC12 cells.
-
In VivoGSK2795039 (intraperitoneal injection; 100 mg/kg; 1 hour before) decreases activity in a murine model of acute pancreatitis, reducing the levels of serum amylase triggered by systemic injection of cerulein. Animal Model:C57BL6 mice Dosage:100 mg/kg Administration:Intraperitoneal injection; 100 mg/kg; 1 hour before Result:Caused 50% reduction in the level of serum amylase activity.
-
Synonyms——
-
PathwayMembrane Transporter/Ion Channel
-
TargetNADPH
-
RecptorNADPH| apoptosis| ROS
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number1415925-18-6
-
Formula Weight450.56
-
Molecular FormulaC23H26N6O2S
-
Purity>98% (HPLC)
-
SolubilityDMSO:31 mg/mL(68.8 mM)
-
SMILESCC(C)n1cc(-c2ccc3CCN(C)c3c2)c2c(NS(=O)(=O)c3ccn(C)n3)ccnc12
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
-
5-Heneicosylresorcin...
5-Heneicosylresorcinol shows inhibitory effects on the release of β-hexosaminidase from RBL-2H3 cells, it also prevents triglyceride accumulation in 3T3-L1 cells. 5-Heneicosylresorcinol has nematicidal activity against nematodes Panagrellus redivivus, Caenothabditis elegans and Bursaphelenchus xylophilus, with ED50 values of 80, 30, and 180 ug/mL, respectively.
-
APX-115
APX-115 (Ewha 18278)?is a first-in-class, orally active, pan-NADPH oxidase (Nox) inhibitor with Ki of 1.08, 0.57, 0.63 nM for Nox1, Nox2, and Nox4, respectively.
-
GSK2795039
GSK2795039 inhibits reactive oxygen species (ROS) production and NADPH consumption. GSK2795039 decreases apoptosis. GSK2795039 is an inhibitor of NADPH oxidase 2 (NOX2) (pIC50: 6 in different cell-free assays). GSK2795039 (25 μM; 24 hours) decreases the combinatory effect of FeSO4 and LPS-increased levels of apoptosis.
